Analysts at SVB Leerink downgraded shares of Moderna Inc. MRNA, -3.45% to underperform from market perform, citing growing "competitive pressure" from other developers of COVID-19 vaccines. Shares of Moderna were down 7.3% in premarket trading on Tuesday. The analysts said it's still likely that the Moderna's coronavirus vaccine candidate will be authorized by the Food and Drug Administration in the fourth quarter of this year "but speed to market has fallen behind competitors." Unlike other drugmakers developing experimental COVID-19 vaccines, such as Johnson & Johnson JNJ, -0.64% and Pfizer Inc. PFE, -0.11%, Moderna does not have any other approved products to buffer the company's revenue-earning potential. Moderna's stock has soared 220.0% so far this year, while the S&P 500 SPX, -0.81% has gained 6.0%.
Reprinted from marketwatch, the copyright all reserved by the original author.
风险提示：本文所述仅代表作者个人观点，不代表 Followme 的官方立场。Followme 不对内容的准确性、完整性或可靠性作出任何保证，对于基于该内容所采取的任何行为，不承担任何责任，除非另有书面明确说明。
暂无评论，立马抢沙发